Cao Xindan, Guo Ziqi, Wei Zhiyuan, Ming Hongfei, Ma Bing, Zhao Yue, Zhang Yue, Guo Lei, Peng Cheng
Department of Ophthalmology, the Fourth Affiliated Hospital of China Medical University, 102 Nanqi Road, Heping District, Shenyang 110005, China.
Department of Ophthalmology, Shenyang Sinqi Eye Hospital, No. 136, Nansanhao Street, Heping District, Shenyang 110001, China.
Cont Lens Anterior Eye. 2025 Feb;48(1):102317. doi: 10.1016/j.clae.2024.102317. Epub 2024 Oct 17.
To investigate the efficacy and safety of 0.01% atropine (AT) in combination with different optical treatments for controlling myopia in Chinese children.
This retrospective study analyzed 341 Chinese children aged 6-11 years with myopia between -0.50 D and -3.0 D between January 2022 and May 2023. The fast-progressing, myopic children received three optical treatments combined with 0.01 % atropine: 75 children with single-vision spectacles and atropine (SV + AT), 162 children with defocus-incorporated multi-segment spectacles and atropine (DIMS + AT), or 104 children with orthokeratology and atropine (OK + AT). The changes in spherical equivalent refraction (SER), axial length (AL), intraocular pressure (IOP), and amplitude of accommodation (AMP) were observed at 6-month and 1-year intervals.
After controlling for baseline variables, at 6 months, the increase in adjusted AL was significantly greater in the SV + AT group than in the DIMS + AT group (difference = 0.13 mm, 95 % CI: 0.07-0.20, P < 0.05) and in the OK + AT group (difference = 0.09 mm, 95 % CI: 0.09-0.17, P < 0.05). A more significant progression in adjusted SER was also observed in the SV + AT group than in the DIMS group (difference = -0.20D, 95 % CI: -0.29 to -0.11, P < 0.05). At 12 months, the greatest increase in adjusted AL was observed in the SV + AT group, with a statistically significant difference of 0.24 mm (95 % CI: 0.19-0.29, P < 0.05) compared with the DIMS group and a difference of 0.19 mm (95 % CI: 0.13-0.25, P < 0.05) compared with the OK + ST group. Similarly, a more significant progression in adjusted SER was observed in the SV + AT group than in the DIMS group (difference = -0.36 D, 95 % CI: -0.48 to -0.24, P < 0.05).
This study suggested that 0.01% atropine combined with DIMS or orthokeratology may be viable for controlling low myopia in fast-progressing, myopic children.
探讨0.01%阿托品(AT)联合不同光学治疗方法控制中国儿童近视的疗效和安全性。
这项回顾性研究分析了2022年1月至2023年5月期间341名年龄在6至11岁、近视度数在-0.50 D至-3.0 D之间的中国儿童。快速进展性近视儿童接受了三种联合0.01%阿托品的光学治疗:75名儿童佩戴单光眼镜并使用阿托品(SV + AT),162名儿童佩戴离焦整合多焦点眼镜并使用阿托品(DIMS + AT),或104名儿童接受角膜塑形术并使用阿托品(OK + AT)。每隔6个月和1年观察等效球镜度(SER)、眼轴长度(AL)、眼压(IOP)和调节幅度(AMP)的变化。
在控制基线变量后,6个月时,SV + AT组调整后的AL增加量显著大于DIMS + AT组(差值 = 0.13 mm,95% CI:0.07 - 0.20,P < 0.05)和OK + AT组(差值 = 0.09 mm,95% CI:0.09 - 0.17,P < 0.05)。SV + AT组调整后的SER进展也比DIMS组更显著(差值 = -0.20D,95% CI:-0.29至-0.11,P < 0.05)。12个月时,SV + AT组调整后的AL增加量最大,与DIMS组相比差异有统计学意义,为0.24 mm(95% CI:0.19 - 0.29,P < 0.05),与OK + ST组相比差异为0.19 mm(95% CI:0.13 - 0.25,P < 0.05)。同样,SV + AT组调整后的SER进展比DIMS组更显著(差值 = -0.36 D,95% CI:-0.48至-0.24,P < 0.05)。
本研究表明,0.01%阿托品联合DIMS或角膜塑形术可能对控制快速进展性近视儿童的低度近视有效。